Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
|Articles|October 12, 2019
AAO 2019 Retina Street Team: Allen C. Ho, MD
Author(s)AAO 2019 Retina Street Team
Advertisement
Allen C. Ho, MD, discusses precision subretinal delivery for gene and cell therapy along with Ben Ko, engineering manager, Kaleidoscope Innovation, at the 2019 meeting of the American Academy of Ophthalmology in San Francisco, CA.
Advertisement
Related to this article
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
2
AAO 2026: BRUNELLO 1-year results for remigromig in DME
3
Clobetasol cuts post-cataract inflammation and pain in phase 3 trial
4
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
5